MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer
<p>In the past few years, immunotherapy, particularly immune checkpoint inhibitors, have redefi ned standard of care cancer treatment for numerous malignancies. However, despite the wealth of promising data and great enthusiasm, the vast majority of cancer patients still fail to respond to the...
Saved in:
Main Author: | Julius Strauss (Author) |
---|---|
Format: | Book |
Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2017-05-26.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current understanding of the cardiotoxicity-related treatment of immune checkpoint inhibitors in breast cancer
by: Jiajing Dai
Published: (2023) -
Immune Checkpoint Molecules and Cancer Immunotherapy
by: Alexandr V. Bazhin
Published: (2019) -
Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023) -
Colorectal Cancer
Published: (2021) -
Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology
by: Benjamin A Babalola, et al.
Published: (2021)